Aktienanalyse zu Firefly Neuroscience Inc (AIFF)AIFFFirefly Neuroscience Inc

Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset. It operates in the Technology sector.

Currently, Firefly Neuroscience Inc. (AIFF) is not a good buy due to its low RSI of 35.016, indicating it is oversold, and a significant 1-year change of -56.88%, reflecting poor performance over the past year. While the stock has shown positive catalysts, such as partnerships that could enhance its market position, the recent 5-day decline of 12.50% and the lack of strong upward momentum suggest caution. The main risk is the company's negative net income, which was -1984000 USD in the latest quarter, indicating ongoing financial struggles.